Collectively, these results support a functional role of the FOSL1 target AURKA in KRAS-driven tumours and unveil the dual inhibition of AURKA and MEK activation as a potential strategy to treat tumours with KRAS mutations. This evidence concerns the gene MAP2K7 and neoplasm.